RBC Capital Cuts Abbott Laboratories (ABT) Price Target to $125

RBC Capital maintained its Outperform rating on Abbott Laboratories NYSE:ABT on October 22, 2026, while lowering its price target to $125.00 from $130.00. The research note arrived alongside a wave of updates from other major financial firms tracking the healthcare giant. Shares of Abbott closed at $102.56 on October 22, 2026.

ABT Abbott Laboratories

$100.51 ▼ -17.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

RBC Capital's Call on Abbott Laboratories

In its October 22, 2026 update, RBC Capital kept an Outperform rating on the medical device maker while trimming the target price down by $5.00 from the previous $130.00 level.

Other Institutional Activity in Abbott Laboratories

Capital International Investors trimmed its holdings by 2,842,222 shares, ending the period with 34,654,113 shares valued at about $3,553,952,569.

Abbott Laboratories Stock Down 0.1%

Abbott recently traded around $102.35 as of October 22, 2026, sitting below its 50-day moving average of $105.49 and right near its 200-day moving average of $102.46. The stock remains well below its 52-week high of $132.03 while staying above its 52-week low of $81.97.

Recent Earnings

Abbott Laboratories reported trailing twelve month revenue of $46,585,000,000 alongside trailing earnings of $2.69 per share.

Dividend

Abbott distributes an annual dividend rate of $2.52 per share, yielding 2.46% with a payout ratio of 78.7%.

Insider Buying and Selling at Abbott Laboratories

Insider transactions included purchases and sales across the executive team. Director John G. Stratton bought 2,000 shares on May 7, 2026, at an average price of $86.82. Officer Louis H. Morrone sold 5,850 shares on August 11, 2026, at an average price of $109.83. Chief Executive Officer Robert B. Ford sold 398,832 shares on August 25, 2026, and officer John A. McCoy Jr. sold 27 shares on September 2, 2026, at an average price of $109.54.

Analysts Set New Price Targets

On October 22, 2026, Wells Fargo maintained its Overweight rating and lifted its price target from $112.00 to $119.00. On the same date, JP Morgan kept an Overweight rating while lowering its target from $120.00 to $118.00. TD Cowen maintained a Buy rating and trimmed its target from $135.00 to $118.00. Baird kept an Outperform rating and raised its target from $121.00 to $123.00. Across Wall Street, analysts hold a consensus Strong Buy recommendation with a mean price target of $120.41 across 26 analyst opinions.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products globally. The enterprise operates across four primary divisions: established pharmaceutical products, diagnostic systems, nutritional goods, and medical devices.

Bottom Line

Investors tracking Abbott will want to monitor upcoming earnings reports and consensus adjustments from major banking institutions. The recent round of target revisions shows steady confidence across the analyst community despite shifting macroeconomic conditions.